Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31081432 | 1.00 | GPR3 (0.54) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL31083546 | 0.90 | HSD17B10 (0.48) | GPR3CYP1A2HSD17B10PTPN22CA2 | |
| SCHEMBL15315656 | 0.89 | GPR3 (0.54) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL14607511 | 0.86 | KDM4E (0.58) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL17037079 | 0.85 | PTPN1 (0.40) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL18903328 | 0.85 | GPR3 (0.50) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL19768707 | 0.82 | GPR3 (0.56) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL11383271 | 0.82 | GPR3 (0.47) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL8672690 | 0.81 | GPR3 (0.54) | GPR3CYP1A2MAPTALDH1A1HPGD | |
| SCHEMBL12075019 | 0.81 | GPR3 (0.54) | GPR3CYP1A2MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019199911-A1 | PHOTOSWITCHABLE DIBENZOTHIENYLMETHYL TRIPHENYLPHOSPHONIUM DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH | SAINT LOUIS UNIVERSITY (US) | 2019-10-17 | — | — | WO | disclosed |
| CN-102442993-A | Compound having dibenzo group and its derivative, process for producing them and use thereof | CHINESE ACAD INST CHEMISTRY | 2012-05-09 | — | — | CN | disclosed |
| US-7772237-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-7772237-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-7772237-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2009-04-23 | — | — | US | disclosed |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2009-04-23 | — | — | US | disclosed |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2009-04-23 | — | — | US | disclosed |
| US-7476690-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2009-01-13 | — | — | US | disclosed |
| US-7476690-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2009-01-13 | — | — | US | disclosed |
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-12-22 | — | — | US | disclosed |
| WO-2005100345-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2005-10-27 | — | — | WO | disclosed |
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
| EP-1109785-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA Medica Aktiengesellschaft (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-1999057117-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-11 | — | — | WO | disclosed |
| US-4845263-A | Layered photoresponsive imaging members with sulfur incorporated dicyanomethylenefluorene carboxylate compositions of matter | XEROX CORPORATION (US) | 1989-07-04 | — | — | US | disclosed |
| US-4546059-A | Layered photoresponsive imaging members with sulfur incorporated dicyanomethylenefluorene carboxylate compositions | XEROX CORPORATION (US) | 1985-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | GPR3 356/4885CYP1A2 484/4885MAPT 1232/4885 |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | HTR1A, HTR2A, HTR5A | GPR3 356/4885CYP1A2 484/4885MAPT 1232/4885 |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | GPR3 2677/4885CYP1A2 585/4885MAPT 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.